Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 13/20 | 0.38 |
| ▸ | KDM6B | O15054 | 11/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | KDM4A | O75164 | 1/20 | 0.34 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2507288 | 0.88 | GRM5 (0.38) | KDM4CKDM6BGRM5IDH1PTGS1 | |
| SCHEMBL2514237 | 0.84 | GRM5 (0.40) | KDM4CKDM6BGRM5IDH1GRM1 | |
| SCHEMBL2511391 | 0.81 | GRM5 (0.38) | KDM4CGRM5IDH1PTGS1PTGS2 | |
| SCHEMBL2509716 | 0.81 | KDM4E (0.38) | KDM4CKDM6BGRM5IDH1KDM4E | |
| SCHEMBL2511387 | 0.81 | PRF1 (0.36) | KDM4CKDM6BGRM5IDH1GRM1 | |
| SCHEMBL2511617 | 0.79 | PRF1 (0.37) | KDM4CKDM6BGRM5IDH1GRM1 | |
| SCHEMBL2512031 | 0.75 | PRF1 (0.38) | GRM5GRM1KDM4EALDH1A1 | |
| SCHEMBL2506683 | 0.75 | GRM5 (0.41) | GRM5IDH1GRM1KDM4EALDH1A1 | |
| SCHEMBL2515759 | 0.74 | MAPT (0.45) | KDM4EALDH1A1 | |
| SCHEMBL2507290 | 0.73 | HDAC6 (0.39) | KDM4CKDM6BGRM5IDH1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664214-B2 | Small molecule potentiators of metabotropic glutamate receptors I | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-03-04 | — | — | US | claimed |
| US-8664214-B2 | Small molecule potentiators of metabotropic glutamate receptors I | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-03-04 | — | — | US | disclosed |
| US-20110245232-A1 | NOVEL SMALL MOLECULE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS I | ABBOTT GMBH & CO. KG (DE) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245232-A1 | NOVEL SMALL MOLECULE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS I | GRM3, GRIN2C, GRIN2B | KDM4C 2588/4885KDM6B 3609/4885GRM5 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.